Elevated serum NSE in inoperable non-small-cell lung carcinoma (NSCLC) is associated with a better response but worse prognosis

Pneumonologia i Alergologia Polska

Volumn 78, Issue 1, 2010, Pages 14-20

  Załeska, Monika ^a   Szturmowicz, Monika ^a   Zych, Jacek ^a   Roszkowska Śliz, Barbara ^a   Demkow, Urszula ^b   Langfort, Renata ^a   Roszkowski Śliz, Kazimierz ^a  

^a NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Neuron specific enolase; Non small cell lung cancer; Prognosis; Response to treatment

Indexed keywords

ANTIGEN CYFRA21.1; ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CYTOKERATIN 19; ENOLASE; FERRITIN; LACTATE DEHYDROGENASE; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; ENZYMOLOGY; FEMALE; HOSPITALIZATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL; SURVIVAL RATE;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; FEMALE; FERRITINS; HUMANS; KERATIN-19; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84866555974     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Barlesi F., Gimenez C., Torre J.P., Doddoli C. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir. Med. 2004; 98: 357-362.
2. Ebert W., Dienemann H., Fateh-Moghadam A., Scheulen M. Cytokeratin 19 fragment CYFRA 21-1 compare with carcinoembryogenic antigen, squamous cell carcinoma antigen and neuron- specific enolase in lung cancer. Eur. J. Clin. Biochem. 1994; 32: 189-199.
3. Ferrigno D., Buccheri G., Biggi A. Serum tumour markers in lung cancer: history, biology and clinical applications. Eur. Respir. J. 1994; 7: 186-197.
4. Ferrigno D., Buccheri G., Giordano C. Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer 2003; 41: 311-320.
5. Van Zandwijk N., Jassem E., Bonfrer J.M., Mooi W.J. Serum neuron specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin. Oncol. 1992; 19: 37-43.
6. Zych J., Szturmowicz M., Sakowicz A. et al. Neuron-specific enolase (NSE) serum level as a prognostic factor in non-small cell lung cancer. Pneumonol. Alergol. Pol. 2002; 70: 278-283.
7. World Health Organization. Histological typing of lung cancer tumors. W: International classification of tumors. 2nd ed. Geneva: WHO, 1981.
8. Reif P.T., Rivera M.P. Evidence-base outcomes for patients with advanced non-small cell leng cancer. Semin. Respir. Crit. Care Med. 2000; 21: 1-16.
9. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1711s-1717s.
10. Moran C.A., Suster S., Coppola D., Wich M.R. Neuroendocrine carcinomas of the lung. A critical analysis. Am. J. Clin. Pathol. 2009; 131: 206-221.
11. Carles J., Rosell R., Ariza A. et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 1993; 10: 209-219.
12. Sundaresan V., Reeve J.G., Stenning S., Stewart S., Bleehen N.M. Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. Br. J. Cancer 1991; 64: 333-338.
13. Linnoila R.I., Piantadosi S., Ruckdeschel J.C. Impact of neuroendocrine differentiation in non-small cell lung cancer. Chest 1994; 106: 367s-371s.
14. Graziano S.L., Tatum A.H., Newman N.B. et al. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res. 1994; 54: 2906-2913.
15. Slodkowska J., Zych J., Szturmowicz M., Demkow U., Rowinska- Zakrzewska E., Roszkowski-Sliz K. Neuroendocrine phenotype of non-small cell lung carcinoma: immunohistological evaluation and biochemical study. Int. J. Biol. Markers 2005; 20: 217-226.
16. Pelosi G., Pasini F., Sonzogni A. et al. Prognostic implications of neuroendocrine differentiation and hormone production in patients with stage I nonsmall cell lung carcinoma. Cancer 2003; 97: 2487-2497.
17. Hiroshima K., Iyoda A., Shibuya K. et al. Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung. Ann. Thorac. Surg. 2002; 73: 1732-1735.
18. Ruibal A., Nunez M.I., Rodriguez J., Jimenez L., del Rio M.C., Zapatero J. Cytosolic levels of neuron-specific enolase in squamous cell carcinomas of the lung. Int. J. Biol. Markers 2003; 18: 188-194.
19. Nisman B., Heching N., Biran H., Barak V., Peretz T. The prognostic significance of circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide and neuron-specific enolase in a patients with advanced non-small-cell lung cancer. Tumor Biol. 2006; 27: 8-16.
20. Pujol J.-L., Boher J.-M., Grenier J., Quantin X. Cyfra 21-1, neuron- specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 2001; 31: 221-231.
21. Maeda T., Ueoka H., Tabata M., Kiura K. Prognostic factors in advanced non-small cell lung cancer: elevated serum level of neuron specific enolase indicate poor prognosis. Jpn. J. Clin. Oncol. 2000; 30: 534-541.
22. Akerley W., Crowley J., Giroux D., Gandara D. Response to chemotherapy as a predictor of survival in advanced nonsmall cell lung cancer (NSCLC): Review of the Southwest Oncology Group (SWOG) database. Lung Cancer 2000; 29 (supl. 1): 33.
23. Betticher D.C., Hsu Schmitz S.F., Tötsch M. et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small cell lung cancer: 5-year follow-up of a phase II study. Br. J. Cancer 2006; 94: 1099-1106.
24. Johnson K.R., Ringland C., Stokes B.J. et al. Response rate or time to progression as predictors of survival in trials of metastatic colonorectal cancer or non-small cell lung cancer: a metaanalysis. Lancet Oncol. 2006; 7: 703-704.
25. Diez M., Torres A., Ortega L. et al. Value of serum neuronspecific enolase in nonsmall cell lung cancer. Oncology 1993; 50: 127-131.
26. Hatzakis K.D., Froudarakis M.E., Bouros D., Tzanakis N., Karkavitsas N., Siafakas N.M. Prognostic value of serum tumor markers in patients with lung cancer. Respiration 2002; 69: 25-29.
27. Foa P., Fornier M., Micelli R., Seregni E. Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer. Int. J. Biol. Markers 1999; 14: 92-98.
28. Reinmuth N., Brandt B., Semik M. et al. Prognostic impact of Cyfra 21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 2002; 36: 265-270.